SEARCH

SEARCH BY CITATION

REFERENCES

  • Auroy S,Avril MF,Chompret A,Pham D,Goldstein AM,Bianchi-Scarra G,Frebourg T,Joly P,Spatz A,Rubino C,Demenais F,Bressac-de Paillerets B. 2001. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32: 195202.
  • Baylin SB,Esteller M,Rountree MR,Bachman KE,Schuebel K,Herman JG. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687692.
  • Beddingfield FC,III. 2003. The melanoma epidemic: res ipsa loquitur. Oncologist 8: 459465.
  • Bishop DT,Demenais F,Goldstein AM,Bergman W,Bishop JN,Bressac-de Paillerets B,Chompret A,Ghiorzo P,Gruis N,Hansson J,Harland M,Hayward N,Holland EA,Mann GJ,Mantelli M,Nancarrow D,Platz A,Tucker MA. 2002. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94: 894903.
  • Brose MS,Volpe P,Feldman M,Kumar M,Rishi I,Gerrero R,Einhorn E,Herlyn M,Minna J,Nicholson A,Roth JA,Albelda SM,Davies H,Cox C,Brignell G,Stephens P,Futreal PA,Wooster R,Stratton MR,Weber BL. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 69977000.
  • Cameron EE,Bachman KE,Myohanen S,Herman JG,Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103107.
  • Carrier A,Nguyen C,Victorero G,Granjeaud S,Rocha D,Bernard K,Miazek A,Ferrier P,Malissen M,Naquet P,Malissen B,Jordan BR. 1999. Differential gene expression in CD3epsilon- and RAG1-deficient thymuses: definition of a set of genes potentially involved in thymocyte maturation. Immunogenetics 50: 255270.
  • Castellano M,Pollock PM,Walters MK,Sparrow LE,Down LM,Gabrielli BG,Parsons PG,Hayward NK. 1997. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57: 48684875.
  • Coolen MW,Statham AL,Gardiner-Garden M,Clark SJ. 2007. Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: Critical evaluation and improvements. Nucleic Acids Res 35: e119.
  • Coory M,Baade P,Aitken J,Smithers M,McLeod GR,Ring I. 2006. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 17: 2127.
  • Coups EJ,Manne SL,Heckman CJ. 2008. Multiple skin cancer risk behaviors in the US Population. Am J Prev Med 34: 8793.
  • Cummins DL,Cummins JM,Pantle H,Silverman MA,Leonard AL,Chanmugam A. 2006. Cutaneous malignant melanoma. Mayo Clin Proc 81: 500507.
  • Curtin JA,Fridlyand J,Kageshita T,Patel HN,Busam KJ,Kutzner H,Cho KH,Aiba S,Brocker EB,LeBoit PE,Pinkel D,Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 21352147.
  • Dai DL,Martinka M,Bush JA,Li G. 2004. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 91: 10891095.
  • Davies H,Bignell GR,Cox C,Stephens P,Edkins S,Clegg S,Teague J,Woffendin H,Garnett MJ,Bottomley W,Davis N,Dicks E,Ewing R,Floyd Y,Gray K,Hall S,Hawes R,Hughes J,Kosmidou V,Menzies A,Mould C,Parker A,Stevens C,Watt S,Hooper S,Wilson R,Jayatilake H,Gusterson BA,Cooper C,Shipley J,Hargrave D,Pritchard-Jones K,Maitland N,Chenevix-Trench G,Riggins GJ,Bigner DD,Palmieri G,Cossu A,Flanagan A,Nicholson A,Ho JW,Leung SY,Yuen ST,Weber BL,Seigler HF,Darrow TL,Paterson H,Marais R,Marshall CJ,Wooster R,Stratton MR,Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949954.
  • Dong J,Phelps RG,Qiao R,Yao S,Benard O,Ronai Z,Aaronson SA. 2003. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 38833885.
  • Ehrich M,Nelson MR,Stanssens P,Zabeau M,Liloglou T,Xinarianos G,Cantor CR,Field JK,van den Boom D. 2005. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102: 1578515790.
  • Forsberg L,Bjorck E,Hashemi J,Zedenius J,Hoog A,Farnebo LO,Reimers M,Larsson C. 2005. Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology. Eur J Endocrinol 152: 459470.
  • Freedberg DE,Rigas SH,Russak J,Gai W,Kaplow M,Osman I,Turner F,Randerson-Moor JA,Houghton A,Busam K,Timothy Bishop D,Bastian BC,Newton-Bishop JA,Polsky D. 2008. Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 100: 784795.
  • Fujimoto A,Takeuchi H,Taback B,Hsueh EC,Elashoff D,Morton DL,Hoon DS. 2004. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64: 22452250.
  • Fujita M,Furukawa Y,Tsunoda T,Tanaka T,Ogawa M,Nakamura Y. 2001. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 61: 77227726.
  • Furuta J,Umebayashi Y,Miyamoto K,Kikuchi K,Otsuka F,Sugimura T,Ushijima T. 2004. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95: 962968.
  • Gallagher WM,Bergin OE,Rafferty M,Kelly ZD,Nolan IM,Fox EJ,Culhane AC,McArdle L,Fraga MF,Hughes L,Currid CA,O'Mahony F,Byrne A,Murphy AA,Moss C,McDonnell S,Stallings RL,Plumb JA,Esteller M,Brown R,Dervan PA,Easty DJ. 2005. Multiple markers for melanoma progression regulated by DNA methylation: Insights from transcriptomic studies. Carcinogenesis 26: 18561867.
  • Giglia-Mari G,Sarasin A. 2003. TP53 mutations in human skin cancers. Hum Mutat 21: 217228.
  • Gorden A,Osman I,Gai W,He D,Huang W,Davidson A,Houghton AN,Busam K,Polsky D. 2003. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63: 39553957.
  • Hammarsund M,Lerner M,Zhu C,Merup M,Jansson M,Gahrton G,Kluin-Nelemans H,Einhorn S,Grander D,Sangfelt O,Corcoran M. 2004. Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia. Hum Mol Genet 13: 29252936.
  • Hernandez MC,Andres-Barquin PJ,Holt I,Israel MA. 1998. Cloning of human ENC-1 and evaluation of its expression and regulation in nervous system tumors. Exp Cell Res 242: 470477.
  • Ito Y,Motoo Y,Yoshida H,Iovanna JL,Nakamura Y,Kuma K,Miyauchi A. 2006a. High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology 38: 545547.
  • Ito Y,Motoo Y,Yoshida H,Iovanna JL,Takamura Y,Miya A,Kuma K,Miyauchi A. 2006b. Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma. Anticancer Res 26: 43914395.
  • Jiang PH,Motoo Y,Garcia S,Iovanna JL,Pebusque MJ,Sawabu N. 2006. Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol 12: 691696.
  • Jing C,El-Ghany MA,Beesley C,Foster CS,Rudland PS,Smith P,Ke Y. 2002. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 94: 482490.
  • Johansson P,Pavey S,Hayward N. 2007. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 20: 216221.
  • Kim TA,Ota S,Jiang S,Pasztor LM,White RA,Avraham S. 2000. Genomic organization, chromosomal localization and regulation of expression of the neuronal nuclear matrix protein NRP/B in human brain tumors. Gene 255: 105116.
  • Kraehn GM,Utikal J,Udart M,Greulich KM,Bezold G,Kaskel P,Leiter U,Peter RU. 2001. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 84: 7279.
  • Leonard JH,Marks LH,Chen W,Cook AL,Boyle GM,Smit DJ,Brown DL,Stow JL,Parsons PG,Sturm RA. 2003. Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies. Pigment Cell Res 16: 198207.
  • Mirmohammadsadegh A,Marini A,Nambiar S,Hassan M,Tannapfel A,Ruzicka T,Hengge UR. 2006. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66: 65466552.
  • Molven A,Grimstvedt MB,Steine SJ,Harland M,Avril MF,Hayward NK,Akslen LA. 2005. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44: 1018.
  • Monzon J,Liu L,Brill H,Goldstein AM,Tucker MA,From L,McLaughlin J,Hogg D,Lassam NJ. 1998. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338: 879887.
  • Mustika R,Budiyanto A,Nishigori C,Ichihashi M,Ueda M. 2005. Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 18: 5962.
  • Muthusamy V,Duraisamy S,Bradbury CM,Hobbs C,Curley DP,Nelson B,Bosenberg M. 2006. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 1118711193.
  • Nagpal S,Patel S,Asano AT,Johnson AT,Duvic M,Chandraratna RA. 1996. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 106: 269274.
  • Okamura S,Arakawa H,Tanaka T,Nakanishi H,Ng CC,Taya Y,Monden M,Nakamura Y. 2001. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 8: 8594.
  • Packer L,Pavey S,Parker A,Stark M,Johansson P,Clarke B,Pollock P,Ringner M,Hayward N. 2006. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 27: 17781786.
  • Pastorino F,Brignole C,Marimpietri D,Pagnan G,Morando A,Ribatti D,Semple SC,Gambini C,Allen TM,Ponzoni M. 2003. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 9: 45954605.
  • Pavey S,Johansson P,Packer L,Taylor J,Stark M,Pollock PM,Walker GJ,Boyle GM,Harper U,Cozzi SJ,Hansen K,Yudt L,Schmidt C,Hersey P,Ellem KA,O'Rourke MG,Parsons PG,Meltzer P,Ringner M,Hayward NK. 2004. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 40604067.
  • Pollock PM,Harper UL,Hansen KS,Yudt LM,Stark M,Robbins CM,Moses TY,Hostetter G,Wagner U,Kakareka J,Salem G,Pohida T,Heenan P,Duray P,Kallioniemi O,Hayward NK,Trent JM,Meltzer PS. 2003. High frequency of BRAF mutations in nevi. Nat Genet 33: 1920.
  • Rothhammer T,Bosserhoff AK. 2007. Epigenetic events in malignant melanoma. Pigment Cell Res 20: 92111.
  • Satyamoorthy K,Li G,Gerrero MR,Brose MS,Volpe P,Weber BL,Van Belle P,Elder DE,Herlyn M. 2003. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756759.
  • Sauter ER,Yeo UC,von Stemm A,Zhu W,Litwin S,Tichansky DS,Pistritto G,Nesbit M,Pinkel D,Herlyn M,Bastian BC. 2002. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62: 32003206.
  • Shutoh M,Oue N,Aung PP,Noguchi T,Kuraoka K,Nakayama H,Kawahara K,Yasui W. 2005. DNA methylation of genes linked with retinoid signaling in gastric carcinoma: Expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer 104: 16091619.
  • Soufir N,Avril MF,Chompret A,Demenais F,Bombled J,Spatz A,Stoppa-Lyonnet D,Benard J,Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French familial melanoma study group. Hum Mol Genet 7: 209216.
  • Tomasini R,Samir AA,Carrier A,Isnardon D,Cecchinelli B,Soddu S,Malissen B,Dagorn JC,Iovanna JL,Dusetti NJ. 2003. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 278: 3772237729.
  • Tomasini R,Samir AA,Vaccaro MI,Pebusque MJ,Dagorn JC,Iovanna JL,Dusetti NJ. 2001. Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J Biol Chem 276: 4418544192.
  • van der Velden PA,Zuidervaart W,Hurks MH,Pavey S,Ksander BR,Krijgsman E,Frants RR,Tensen CP,Willemze R,Jager MJ,Gruis NA. 2003. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer 106: 472479.
  • van Elsas A,Zerp SF,van der Flier S,Kruse KM,Aarnoudse C,Hayward NK,Ruiter DJ,Schrier PI. 1996. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149: 883893.
  • Walker GJ,Flores JF,Glendening JM,Lin AH,Markl ID,Fountain JW. 1998. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22: 157163.
  • Whiteman DC,Milligan A,Welch J,Green AC,Hayward NK. 1997. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 89: 1460.
  • Yokota N,Mainprize TG,Taylor MD,Kohata T,Loreto M,Ueda S,Dura W,Grajkowska W,Kuo JS,Rutka JT. 2004. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 23: 34443453.
  • Youssef EM,Chen XQ,Higuchi E,Kondo Y,Garcia-Manero G,Lotan R,Issa JP. 2004. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64: 24112417.
  • Zhao L,Gregoire F,Sul HS. 2000. Transient induction of ENC-1, a Kelch-related actin-binding protein, is required for adipocyte differentiation. J Biol Chem 275: 1684516850.
  • Zhou XP,Gimm O,Hampel H,Niemann T,Walker MJ,Eng C. 2000. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157: 11231128.
  • Zuo L,Weger J,Yang Q,Goldstein AM,Tucker MA,Walker GJ,Hayward N,Dracopoli NC. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 9799.